[1] ABUNA R P F, ALMEIDA L O, SOUZA A T P, et al. Osteoporosis and osteoblasts cocultured with adipocytes inhibit osteoblast differentiation by downregulating histone acetylation [J]. J Cell Physiol, 2021, 236(5): 3906-17.
[2] Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis [J]. Am J Med, 1993, 94(6): 646-50.
[3] HSIEH C-I, ZHENG K, LIN C, et al. Automated bone mineral density prediction and fracture risk assessment using plain radiographs via deep learning [J]. Nat Commun, 2021, 12(1): 5472.
[4] STONE K L, SEELEY D G, LUI L-Y, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures [J]. J Bone Miner Res, 2003, 18(11): 1947-54.
[5] EBELING P R, NGUYEN H H, ALEKSOVA J, et al. Secondary Osteoporosis [J]. Endocr Rev, 2022, 43(2): 240-313.
[6] KHOSLA S, HOFBAUER L C. Osteoporosis treatment: recent developments and ongoing challenges [J]. Lancet Diabetes Endocrinol, 2017, 5(11): 898 -907.
[7] SHANE E, BURR D, ABRAHAMSEN B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research [J]. J Bone Miner Res, 2014, 29(1).
[8] KHOSLA S, BURR D, CAULEY J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research [J]. J Bone Miner Res, 2007, 22(10): 1479-91.
[9] REID I R, MILLER P D, BROWN J P, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies [J]. J Bone Miner Res, 2010, 25(10): 2256-65.
[10] CUMMINGS S R, FERRARI S, EASTELL R, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo -Controlled FREEDOM Trial and Its Extension [J]. J Bone Miner Res, 2018, 33(2): 190-8.
[11] RACHNER T D, KHOSLA S, HOFBAUER L C. Osteoporosis: now and the future [J]. Lancet, 2011, 377(9773): 1276-87.
[12] CHAVASSIEUX P, CHAPURLAT R, PORTERO-MUZY N, et al. Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment [J]. J Bone Miner Res, 2019, 34(9): 1597-608.
[13] SAAG K G, PETERSEN J, BRANDI M L, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis [J]. N Engl J Med, 2017, 377(15): 1417-27.
[14] GHABEN A L, SCHERER P E. Adipogenesis and metabolic health [J]. Nat Rev Mol Cell Biol, 2019, 20(4): 242-58.
[15] YANG X, LI J, ZHAO L, et al. Targeting adipocytic discoidin domain receptor 2 impedes fat gain while increasing bone mass [J]. Cell Death Differ, 2022, 29(4): 737 -49.
[16] KAHN C R, WANG G, LEE K Y. Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome [J]. J Clin Invest, 2019, 129(10): 3990 -4000.
[17] ROODMAN G D. Mechanisms of bone metastasis [J]. New England journal of medicine, 2004, 350(16): 1655-64.
[18] ORGANIZATION W H. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group [meeting held in Rome from 22 to 25 June 1992] [M]. World Health Organization, 1994.
[19] CASCIARO S, RENNA M, CONVERSANO F, et al. Clinical evaluation of a novel ultrasound-based methodology for osteoporosis diagnosis on overweight and obese women; proceedings of the Proc of 3rd Imeko TC13 Symp on Measurements in Biology and Medicine‘New Frontiers in Biomedical Measurements’, Lecce, Italy, F, 2014 [C].
[20] ESTELL E G, ROSEN C J. Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis [J]. Nature Reviews Endocrinology, 2021, 17(1): 31-46.
[21] JULIET E, COMPSTON M. R. & McClung, WDL Osteoporosis [J]. Lancet, 2019, 393: 364-76.
[22] ALLISTON T, DERYNCK R. Interfering with bone remodelling [J]. Nature, 2002, 416(6882): 686-7.
[23] ANASTASILAKIS A D, POLYZOS S A, MAKRAS P. Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis [J]. European journal of endocrinology, 2018, 179(1): R31-R45.
[24] WALALLAWITA U S, WOLBER F M, ZIV-GAL A, et al. Potential role of lycopene in the prevention of postmenopausal bone loss: Evidence from molecular to clinical studies [J]. International journal of molecular sciences, 2020, 21(19): 7119.
[25] CHEVALIER C, KIESER S, ÇOLAKOĞLU M, et al. Warmth prevents bone loss through the gut microbiota [J]. Cell Metab, 2020, 32(4): 575-90. e7.
[26] CORRADO A, CICI D, ROTONDO C, et al. Molecular basis of bone aging [J]. International journal of molecular sciences, 2020, 21(10): 3679.
[27] FRANCIS K, ASPRAY T, HIDE G, et al. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [J]. Osteoporos Int, 2004, 15(2)): 108-12.
[28] CHIN K-Y, IMA-NIRWANA S. The role of tocotrienol in preventing male osteoporosis—A review of current evidence [J]. International journal of molecular sciences, 2019, 20(6): 1355.
[29] SHEN J, LESLIE W D, NIELSON C M, et al. Associations of body mass index with incident fractures and hip structural parameters in a large Canadian cohort [J]. The Journal of Clinical Endocrinology & Metabolism, 2016, 101(2): 476 -84.
[30] GóMEZ-CABELLO A, ARA I, GONZáLEZ-AGüERO A, et al. Effects of training on bone mass in older adults: a systematic review [J]. Sports Medicine, 2012, 42: 301 -25.
[31] ZHANG Y, CHEN Y, SUN H, et al. SENP3-mediated PPARγ2 DeSUMOylation in BM-MSCs potentiates glucocorticoid-induced osteoporosis by promoting adipogenesis and weakening osteogenesis [J]. Frontiers in Cell and Developmental Biology, 2021, 9: 693079.
[32] CHOI M H, LEE K, KIM M Y, et al. Pisidium coreanum inhibits multinucleated osteoclast formation and prevents estrogen-deficient osteoporosis [J]. International Journal of Molecular Sciences, 2019, 20(23): 6076.
[33] HSIEH C-I, ZHENG K, LIN C, et al. Automated bone mineral density prediction and fracture risk assessment using plain radiographs via deep learning [J]. Nat Commun, 2021, 12(1): 5472.
[34] ZHANG L, CHOI H J, ESTRADA K, et al. Multistage genome-wide association metaanalyses identified two new loci for bone mineral density [J]. Human molecular genetics, 2014, 23(7): 1923-33.
[35] WANG L, YU W, YIN X, et al. Prevalence of Osteoporosis and Fracture in China: The China Osteoporosis Prevalence Study [J]. JAMA Netw Open, 2021, 4(8): e2121106.
[36] 高嘉文. 环状 RNA circRBM23 调控骨髓间充质干细胞成骨成脂分化的机制研究[D]; 南方医科大学, 2023.
[37] GAO C, SONG H, CHEN B, et al. The Assessment of the osteoporosis self-assessment tool for asians and calcaneal quantitative ultrasound in identifying osteoporotic fractures and falls among chinese people [J]. Frontiers in Endocrinology, 2021, 12: 684334.
[38] 中国骨质疏松症流行病学调查及“健康骨骼”专项行动结果发布 [J]. 中华骨质疏松和骨矿盐疾病杂志, 2019, 12(04): 317-8.
[39] LONG G, LIU C, LIANG T, et al. Predictors of osteoporotic fracture in postmenopausal women: a meta-analysis [J]. J Orthop Surg Res, 2023, 18(1): 574.
[40] Epidemiology of Osteoporosis and Fragility Fractures [J/OL] 2024 -02-08 https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures.
[41] REID I R, BILLINGTON E O. Drug therapy for osteoporosis in older adults [J]. Lancet, 2022, 399(10329): 1080-92.
[42] COMPSTON J E, MCCLUNG M R, LESLIE W D. Osteoporosis [J]. Lancet, 2019, 393(10169): 364-76.
[43] KATOH M, KATOH M. Molecular genetics and targeted therapy of WNT-related human diseases (Review) [J]. Int J Mol Med, 2017, 40(3): 587-606.
[44] LEWIECKI E M. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases [J]. Ther Adv Musculoskelet Dis, 2014, 6(2): 48 -57.
[45] VESTERGAARD KVIST A, FARUQUE J, VALLEJO-YAGüE E, et al. Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) [J]. J Clin Med, 2021, 10(8).
[46] SAAG K G, PETERSEN J, BRANDI M L, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis [J]. New England Journal of Medicine, 2017, 377(15): 1417-27.
[47] COSMAN F, CRITTENDEN D B, ADACHI J D, et al. Romosozumab treatment in postmenopausal women with osteoporosis [J]. New England Journal of Medicine, 2016, 375(16): 1532-43.
[48] FIXEN C, TUNOA J. Romosozumab: a review of efficacy, safety, and cardiovascular risk [J]. Current osteoporosis reports, 2021, 19: 15-22.
[49] UNNANUNTANA A, GLADNICK B P, LANE J M. Osteoporosis and the Aging Spine: Diagnosis and Treatment [J]. The Comprehensive Treatment of the Aging Spine EBook: Minimally Invasive and Advanced Techniques-Expert Consult, 2010: 68.
[50] ROSEN C J. The epidemiology and pathogenesis of osteoporosis [J]. 2015.
[51] UCER S, IYER S, KIM H N, et al. The effects of aging and sex steroid deficiency on the murine skeleton are independent and mechanistically distinct [J]. Journal of Bone and Mineral Research, 2017, 32(3): 560-74.
[52] CUMMINGS S R, NEVITT M C, BROWNER W S, et al. Risk factors for hip fracture in white women [J]. New England journal of medicine, 1995, 332(12): 767 -73.
[53] COOPER C. Epidemiology of osteoporosis [J]. Osteoporosis international, 1999, 9: S2.
[54] ROSEN C J. The Epidemiology and Pathogenesis of Osteoporosis [M]//FEINGOLD K R, ANAWALT B, BLACKMAN M R, et al. Endotext. South Dartmouth (MA); MDText.com, Inc.Copyright © 2000-2024, MDText.com, Inc. 2000.
[55] LEAN J M, JAGGER C J, KIRSTEIN B, et al. Hydrogen Peroxide Is Essential for Estrogen-Deficiency Bone Loss and Osteoclast Formation [J]. Endocrinology, 2005, 146(2): 728-35.
[56] LEAN J M, DAVIES J T, FULLER K, et al. A crucial role for thiol antioxidants in estrogen-deficiency bone loss [J]. J Clin Invest, 2003, 112(6): 915-23.
[57] MANOLAGAS S C. From Estrogen-Centric to Aging and Oxidative Stress: A Revised Perspective of the Pathogenesis of Osteoporosis [J]. Endocr Rev, 2010, 31(3): 266 -300.
[58] HARMAN D. Aging: A Theory Based on Free Radical and Radiation Chemistry [J]. Journal of Gerontology, 1956, 11(3): 298-300.
[59] HARMAN D. Aging: a theory based on free radical and radiation chemistry [J]. Science of Aging Knowledge Environment, 2002, 2002(37): cp14-cp.
[60] WEITZMANN M N, ROGGIA C, TORALDO G, et al. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency [J]. J Clin Invest, 2002, 110(11): 1643-50.
[61] GILBERT L, HE X, FARMER P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-α [J]. Endocrinology, 2000, 141(11): 3956-64.
[62] CENCI S, TORALDO G, WEITZMANN M N, et al. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-γ-induced class II transactivator [J]. Proceedings of the National Academy of Sciences, 2003, 100(18): 10405-10.
[63] OIKONOMOU E K, ANTONIADES C. The role of adipose tissue in cardiovascular health and disease [J]. Nat Rev Cardiol, 2019, 16(2): 83-99.
[64] BARTELT A, WIDENMAIER S B, SCHLEIN C, et al. Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity [J]. Nat Med, 2018, 24(3): 292-303.
[65] CYPESS A M. Reassessing Human Adipose Tissue [J]. N Engl J Med, 2022, 386(8): 768-79.
[66] LUMENG C N, BODZIN J L, SALTIEL A R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization [J]. J Clin Invest, 2007, 117(1): 175 -84.
[67] MARGARITIS M, ANTONOPOULOS A S, DIGBY J, et al. Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels [J]. Circulation, 2013, 127(22): 2209-21.
[68] XIE Z, WANG X, LIU X, et al. Adipose-Derived Exosomes Exert Proatherogenic Effects by Regulating Macrophage Foam Cell Formation and Polarization [J]. J Am Heart Assoc, 2018, 7(5).
[69] THOMOU T, MORI M A, DREYFUSS J M, et al. Adipose-derived circulating miRNAs regulate gene expression in other tissues [J]. Nature, 2017, 542(7642): 450 -5.
[70] LEE Y-C, CHANG H-H, CHIANG C-L, et al. Role of perivascular adipose tissuederived methyl palmitate in vascular tone regulation and pathogenesis of hypertension [J]. Circulation, 2011, 124(10): 1160-71.
[71] ROSEN E D, SARRAF P, TROY A E, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro [J]. Mol Cell, 1999, 4(4): 611 -7.
[72] GASTALDELLI A, CASOLARO A, CIOCIARO D, et al. Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients [J]. Am J Physiol Endocrinol Metab, 2009, 297(1): E225-E30.
[73] PRENTICE K J, SAKSI J, ROBERTSON L T, et al. A hormone complex of FABP4 and nucleoside kinases regulates islet function [J]. Nature, 2021, 600(7890): 720-6.
[74] LODHI I J, YIN L, JENSEN-URSTAD A P L, et al. Inhibiting adipose tissue lipogenesis reprograms thermogenesis and PPARγ activation to decrease diet-induced obesity [J]. Cell Metab, 2012, 16(2): 189-201.
[75] GUILHERME A, PEDERSEN D J, HENCHEY E, et al. Adipocyte lipid synthesis coupled to neuronal control of thermogenic programming [J]. Mol Metab, 2017, 6(8): 781-96.
[76] AKOUMIANAKIS I, TARUN A, ANTONIADES C. Perivascular adipose tissue as a regulator of vascular disease pathogenesis: identifying novel therapeutic targets [J]. British Journal of Pharmacology, 2017, 174(20): 3411-24.
[77] YUDKIN J S, ERINGA E, STEHOUWER C D A. "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease [J]. Lancet (London, England), 2005, 365(9473): 1817-20.
[78] VILAHUR G, BEN-AICHA S, BADIMON L. New insights into the role of adipose tissue in thrombosis [J]. Cardiovasc Res, 2017, 113(9): 1046-54.
[79] KING A L, POLHEMUS D J, BHUSHAN S, et al. Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase-nitric oxide dependent [J]. Proc Natl Acad Sci U S A, 2014, 111(8): 3182-7.
[80] YAMAMOTO K, KIYOHARA T, MURAYAMA Y, et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease [J]. Gut, 2005, 54(6): 789-96.
[81] RENUKARADHYA G J, KHAN M A, VIEIRA M, et al. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma [J]. Blood, 2008, 111(12): 5637-45.
[82] QUAIL D F, DANNENBERG A J. The obese adipose tissue microenvironment in cancer development and progression [J]. Nature Reviews Endocrinology, 2019, 15(3): 139-54.
[83] RANA B M J, JOU E, BARLOW J L, et al. A stromal cell niche sustains ILC2-mediated type-2 conditioning in adipose tissue [J]. J Exp Med, 2019, 216(9): 1999-2009.
[84] MOLOFSKY A B, NUSSBAUM J C, LIANG H-E, et al. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages [J]. J Exp Med, 2013, 210(3): 535-49.
[85] ZHANG Z, SCHERER P E. Adipose tissue: The dysfunctional adipocyte - a cancer cell's best friend [J]. Nature Reviews Endocrinology, 2018, 14(3): 132 -4.
[86] KIM J-Y, VAN DE WALL E, LAPLANTE M, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue [J]. J Clin Invest, 2007, 117(9): 2621-37.
[87] YAMAUCHI T, KAMON J, WAKI H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity [J]. Nat Med, 2001, 7(8): 941-6.
[88] ZENG W, PIRZGALSKA R M, PEREIRA M M A, et al. Sympathetic neuro-adipose connections mediate leptin-driven lipolysis [J]. Cell, 2015, 163(1): 84-94.
[89] IYENGAR N M, ZHOU X K, GUCALP A, et al. Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer [J]. Clin Cancer Res, 2016, 22(9): 2283-9.
[90] YUE R, ZHOU B O, SHIMADA I S, et al. Leptin Receptor Promotes Adipogenesis and Reduces Osteogenesis by Regulating Mesenchymal Stromal Cells in Adult Bone Marrow [J]. Cell Stem Cell, 2016, 18(6): 782-96.
[91] DUCY P, AMLING M, TAKEDA S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass [J]. Cell, 2000, 100(2): 197 -207.
[92] HU H, LUO S, LAI P, et al. ANGPTL4 binds to the leptin receptor to regulate ectopic bone formation [J]. Proc Natl Acad Sci U S A, 2024, 121(1): e2310685120.
[93] LEWIS J W, EDWARDS J R, NAYLOR A J, et al. Adiponectin signalling in bone homeostasis, with age and in disease [J]. Bone Res, 2021, 9(1): 1.
[94] LUO X H, GUO L J, XIE H, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway [J]. J Bone Miner Res, 2006, 21(10): 1648-56.
[95] PAL CHINA S, SANYAL S, CHATTOPADHYAY N. Adiponectin signaling and its role in bone metabolism [J]. Cytokine, 2018, 112: 116-31.
[96] 欧阳思维, 樊洁, 汪玉堂, et al. 脂联素与女性身体成分和骨密度的研究进展 [J]. Chinese Journal of Osteoporosis/Zhongguo Guzhi Shusong Zazhi, 2022, 28(5).
[97] KHALAFI M, HOSSEIN SAKHAEI M, KHERADMAND S, et al. The impact of exercise and dietary interventions on circulating leptin and adiponectin in individuals who are overweight and those with obesity: A systematic review and meta -analysis [J]. Adv Nutr, 2023, 14(1): 128-46.
[98] DAS U N. Is obesity an inflammatory condition? [J]. Nutrition, 2001, 17(11-12): 953-66.
[99] KERSHAW E E, FLIER J S. Adipose tissue as an endocrine organ [J]. J Clin Endocrinol Metab, 2004, 89(6): 2548-56.
[100] RODAN G A. Introduction to bone biology [J]. Bone, 1992, 13 Suppl 1: S3 -6.
[101] RICHARDS C D, LANGDON C, DESCHAMPS P, et al. Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone [J]. Cytokine, 2000, 12(6): 613-21.
[102] TSENG W, LU J, BISHOP G A, et al. Regulation of interleukin-6 expression in osteoblasts by oxidized phospholipids [J]. J Lipid Res, 2010, 51(5): 1010 -6.
[103] HAN Y, YOU X, XING W, et al. Paracrine and endocrine actions of bone -the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts [J]. Bone Res, 2018, 6: 16.
[104] FRANCHIMONT N, WERTZ S, MALAISE M. Interleukin-6: An osteotropic factor influencing bone formation? [J]. Bone, 2005, 37(5): 601-6.
[105] SIMS N A, JENKINS B J, QUINN J M, et al. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways [J]. J Clin Invest, 2004, 113(3): 379-89.
[106] GAO H, ZHONG Y, LIN S, et al. Bone marrow adipoq(+) cell population controls bone mass via sclerostin in mice [J]. Signal Transduct Target Ther, 2023, 8(1): 265.
[107] PARACHA N, MASTROKOSTAS P, KELLO E, et al. Osteocalcin improves glucose tolerance, insulin sensitivity and secretion in older male mice [J]. Bone, 2024: 117048.
[108] PEI L, TONTONOZ P. Fat's loss is bone's gain [J]. J Clin Invest, 2004, 113(6): 805 -6.
[109] TAKADA I, KOUZMENKO A P, KATO S. Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis [J]. Nat Rev Rheumatol, 2009, 5(8): 442 -7.
[110] BAGCHI D P, MACDOUGALD O A. Wnt Signaling: From Mesenchymal Cell Fate to Lipogenesis and Other Mature Adipocyte Functions [J]. Diabetes, 2021, 70(7): 1419-30.
[111] PEPTAN I A, HONG L, MAO J J. Comparison of osteogenic potentials of visceral and subcutaneous adipose-derived cells of rabbits [J]. Plast Reconstr Surg, 2006, 117(5): 1462-70.
[112] ANTONIO-VILLA N E, JUáREZ-ROJAS J G, POSADAS-SáNCHEZ R, et al. Visceral adipose tissue is an independent predictor and mediator of the progression of coronary calcification: a prospective sub-analysis of the GEA study [J]. Cardiovasc Diabetol, 2023, 22(1): 81.
[113] PENG K, PAN Y, LI J, et al. 11β-Hydroxysteroid Dehydrogenase Type 1(11β-HSD1) mediates insulin resistance through JNK activation in adipocytes [J]. Sci Rep, 2016, 6: 37160.
[114] KOLB H. Obese visceral fat tissue inflammation: from protective to detrimental? [J]. BMC Med, 2022, 20(1): 494.
[115] TREMBLAY E J, TCHERNOF A, PELLETIER M, et al. Plasma adiponectin/leptin ratio associates with subcutaneous abdominal and omental adipose tissue characteristics in women [J]. BMC Endocr Disord, 2024, 24(1): 39.
[116] WATT J, SCHLEZINGER J J. Structurally-diverse, PPARγ-activating environmental toxicants induce adipogenesis and suppress osteogenesis in bone marrow mesenchymal stromal cells [J]. Toxicology, 2015, 331: 66-77.
[117] KIRKLAND J L, TCHKONIA T, PIRTSKHALAVA T, et al. Adipogenesis and aging: does aging make fat go MAD? [J]. Exp Gerontol, 2002, 37(6): 757 -67.
[118] MA X, WANG D, ZHAO W, et al. Deciphering the Roles of PPARγ in Adipocytes via Dynamic Change of Transcription Complex [J]. Front Endocrinol (Lausanne), 2018, 9: 473.
[119] HOTTA K, BODKIN N L, GUSTAFSON T A, et al. Age-related adipose tissue mRNA expression of ADD1/SREBP1, PPARgamma, lipoprotein lipase, and GLUT4 glucose transporter in rhesus monkeys [J]. J Gerontol A Biol Sci Med Sci, 1999, 54(5): B183-8.
[120] 李园. 宁夏地区 296 例绝经后女性 ALOX12 基因多态性和 BMI、骨密度的关系[D]; 宁夏医科大学, 2018.
[121] MATSUSHITA Y, ONO W, ONO N. Toward Marrow Adipocytes: Adipogenic Trajectory of the Bone Marrow Stromal Cell Lineage [J]. Front Endocrinol (Lausanne), 2022, 13: 882297.
[122] DUQUE G, LI W, VIDAL C, et al. Pharmacological inhibition of PPARγ increases osteoblastogenesis and bone mass in male C57BL/6 mice [J]. J Bone Miner Res, 2013, 28(3): 639-48.
[123] MARCIANO D P, KURUVILLA D S, BOREGOWDA S V, et al. Pharmacological repression of PPARγ promotes osteogenesis [J]. Nat Commun, 2015, 6: 7443.
[124] CHEN Q, SHOU P, ZHENG C, et al. Fate decision of mesenchymal stem cells: adipocytes or osteoblasts? [J]. Cell Death & Differentiation, 2016, 23(7): 1128 -39.
[125] ROSS S E, HEMATI N, LONGO K A, et al. Inhibition of adipogenesis by Wnt signaling [J]. Science, 2000, 289(5481): 950-3.
[126] SHEN G, REN H, SHANG Q, et al. Foxf1 knockdown promotes BMSC osteogenesis in part by activating the Wnt/β-catenin signalling pathway and prevents ovariectomy induced bone loss [J]. EBioMedicine, 2020, 52: 102626.
[127] LEE W C, GUNTUR A R, LONG F, et al. Energy Metabolism of the Osteoblast: Implications for Osteoporosis [J]. Endocr Rev, 2017, 38(3): 255-66.
[128] YANG LOUREIRO Z, JOYCE S, DESOUZA T, et al. Wnt signaling preserves progenitor cell multipotency during adipose tissue development [J]. Nat Metab, 2023, 5(6): 1014-28.
[129] WILLIAMS B O, INSOGNA K L. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone [J]. J Bone Miner Res, 2009, 24(2): 171 -8.
[130] REN Q, CHEN J, LIU Y. LRP5 and LRP6 in Wnt Signaling: Similarity and Divergence [J]. Front Cell Dev Biol, 2021, 9: 670960.
[131] CANALIS E. Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches [J]. Nature Reviews Endocrinology, 2013, 9(10): 575-83.
[132] MAEDA K, KOBAYASHI Y, KOIDE M, et al. The Regulation of Bone Metabolism and Disorders by Wnt Signaling [J]. International Journal of Molecular Sciences, 2019, 20(22): 5525.
[133] CUI Y, NIZIOLEK P J, MACDONALD B T, et al. Lrp5 functions in bone to regulate bone mass [J]. Nature Medicine, 2011, 17(6): 684-91.
[134] LITTMAN J, YANG W, OLANSEN J, et al. LRP5, Bone Mass Polymorphisms and Skeletal Disorders [J]. Genes (Basel), 2023, 14(10).
[135] PAPADOPOULOS I, BOUNTOUVI E, ATTILAKOS A, et al. Osteoporosispseudoglioma syndrome: clinical, genetic, and treatment-response study of 10 new cases in Greece [J]. Eur J Pediatr, 2019, 178(3): 323-9.
[136] DIEGEL C R, KRAMER I, MOES C, et al. Inhibiting WNT secretion reduces high bone mass caused by Sost loss-of-function or gain-of-function mutations in Lrp5 [J]. Bone Research, 2023, 11(1): 47.
[137] WHYTE M P, MCALISTER W H, ZHANG F, et al. New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6 [J]. Bone, 2019, 127: 228-43.
[138] WU M, CHEN G, LI Y-P. TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease [J]. Bone Research, 2016, 4(1): 16009.
[139] DENTON N F, EGHLEILIB M, AL-SHARIFI S, et al. Bone morphogenetic protein 2 is a depot-specific regulator of human adipogenesis [J]. Int J Obes (Lond), 2019, 43(12): 2458-68.
[140] WU M, WU S, CHEN W, et al. The roles and regulatory mechanisms of TGF-β and BMP signaling in bone and cartilage development, homeostasis and disease [J]. Cell Res, 2024, 34(2): 101-23.
[141] HALLORAN D, DURBANO H W, NOHE A. Bone Morphogenetic Protein-2 in Development and Bone Homeostasis [J]. J Dev Biol, 2020, 8(3).
[142] TANG Q Q, OTTO T C, LANE M D. Commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage [J]. Proc Natl Acad Sci U S A, 2004, 101(26): 9607 -11.
[143] RAHMAN M S, AKHTAR N, JAMIL H M, et al. TGF-β/BMP signaling and other molecular events: regulation of osteoblastogenesis and bone formation [J]. Bone Research, 2015, 3(1): 15005.
[144] SCHREIBER I, DöRPHOLZ G, OTT C-E, et al. BMPs as new insulin sensitizers: enhanced glucose uptake in mature 3T3-L1 adipocytes via PPARγ and GLUT4 upregulation [J]. Scientific Reports, 2017, 7(1): 17192.
[145] WANG E A, ISRAEL D I, KELLY S, et al. Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells [J]. Growth Factors, 1993, 9(1): 57-71.
[146] GHOSH-CHOUDHURY N, ABBOUD S L, NISHIMURA R, et al. Requirement of BMP-2-induced phosphatidylinositol 3-kinase and Akt serine/threonine kinase in osteoblast differentiation and Smad-dependent BMP-2 gene transcription [J]. J Biol Chem, 2002, 277(36): 33361-8.
[147] XU X, ZHENG L, YUAN Q, et al. Transforming growth factor-β in stem cells and tissue homeostasis [J]. Bone Research, 2018, 6(1): 2.
[148] BONEWALD L F, DALLAS S L. Role of active and latent transforming growth factor beta in bone formation [J]. J Cell Biochem, 1994, 55(3): 350-7.
[149] CENTRELLA M, HOROWITZ M C, WOZNEY J M, et al. Transforming growth factor-beta gene family members and bone [J]. Endocr Rev, 1994, 15(1): 27 -39.
[150] CALVIER L, CHOUVARINE P, LEGCHENKO E, et al. PPARγ Links BMP2 and TGFβ1 Pathways in Vascular Smooth Muscle Cells, Regulating Cell Proliferation and Glucose Metabolism [J]. Cell Metab, 2017, 25(5): 1118-34.e7.
[151] PATEL K D, NGUYEN D X. Condensing and constraining WNT by TGF-β [J]. Nat Cell Biol, 2021, 23(3): 213-4.
[152] YOUSEFI F, SHABANINEJAD Z, VAKILI S, et al. TGF-β and WNT signaling pathways in cardiac fibrosis: non-coding RNAs come into focus [J]. Cell Commun Signal, 2020, 18(1): 87.
[153] UCCELLI A, MORETTA L, PISTOIA V. Mesenchymal stem cells in health and disease [J]. Nat Rev Immunol, 2008, 8(9): 726-36.
[154] PLATOVA S, POLIUSHKEVICH L, KULAKOVA M, et al. Gotta Go Slow: Two Evolutionarily Distinct Annelids Retain a Common Hedgehog Pathway Composition, Outlining Its Pan-Bilaterian Core [J]. Int J Mol Sci, 2022, 23(22).
[155] XU S, TANG C. Cholesterol and Hedgehog Signaling: Mutual Regulation and Beyond [J]. Front Cell Dev Biol, 2022, 10: 774291.
[156] WU Q, TIAN P, HE D, et al. SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches [J]. Cell Res, 2023, 33(6): 464-78.
[157] CHEN L, LIU G, LI W, et al. Chondrogenic differentiation of bone marrow-derived mesenchymal stem cells following transfection with Indian hedgehog and sonic hedgehog using a rotary cell culture system [J]. Cell Mol Biol Lett, 2019, 24: 16.
[158] NAKAMURA T, NARUSE M, CHIBA Y, et al. Novel hedgehog agonists promote osteoblast differentiation in mesenchymal stem cells [J]. J Cell Physiol, 2015, 230(4): 922-9.
[159] KUWAHARA S T, LIU S, CHAREUNSOUK A, et al. On the horizon: Hedgehog signaling to heal broken bones [J]. Bone Research, 2022, 10(1): 13.
[160] JING J, WU Z, WANG J, et al. Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies [J]. Signal Transduct Target Ther, 2023, 8(1): 315.
[161] ZEHENTNER B K, LESER U, BURTSCHER H. BMP-2 and sonic hedgehog have contrary effects on adipocyte-like differentiation of C3H10T1/2 cells [J]. DNA Cell Biol, 2000, 19(5): 275-81.
[162] FONTAINE C, COUSIN W, PLAISANT M, et al. Hedgehog signaling alters adipocyte maturation of human mesenchymal stem cells [J]. Stem Cells, 2008, 26(4): 1037 -46.
[163] AHMAD B, SERPELL C J, FONG I L, et al. Molecular Mechanisms of Adipogenesis: The Anti-adipogenic Role of AMP-Activated Protein Kinase [J]. Front Mol Biosci, 2020, 7: 76.
[164] ROSEN E D, MACDOUGALD O A. Adipocyte differentiation from the inside out [J]. Nature Reviews Molecular Cell Biology, 2006, 7(12): 885-96.
[165] CHEN J, BAO C, KIM J T, et al. Sulforaphene Inhibition of Adipogenesis via Hedgehog Signaling in 3T3-L1 Adipocytes [J]. J Agric Food Chem, 2018, 66(45): 11926-34.
[166] SUH J M, GAO X, MCKAY J, et al. Hedgehog signaling plays a conserved role in inhibiting fat formation [J]. Cell Metab, 2006, 3(1): 25-34.
[167] KIM W K, MELITON V, AMANTEA C M, et al. 20(S)-hydroxycholesterol inhibits PPARgamma expression and adipogenic differentiation of bone marrow stromal cells through a hedgehog-dependent mechanism [J]. J Bone Miner Res, 2007, 22(11): 1711-9.
[168] KARSENTY G, KHOSLA S. The crosstalk between bone remodeling and energy metabolism: A translational perspective [J]. Cell Metab, 2022, 34(6): 805 -17.
[169] LIU H, LIU S, JI H, et al. An adiponectin receptor agonist promote osteogenesis via regulating bone-fat balance [J]. Cell Prolif, 2021, 54(6): e13035.
[170] SHANG J, YU Z, XIONG C, et al. Resistin targets TAZ to promote osteogenic differentiation through PI3K/AKT/mTOR pathway [J]. iScience, 2023, 26(7): 107025.
[171] TARIQ S, TARIQ S, KHALIQ S, et al. Serum Resistin Levels and Related Genetic Variants Are Associated With Bone Mineral Density in Postmenopausal Women [J]. Front Endocrinol (Lausanne), 2022, 13: 868120.
[172] DAI B, XU J, LI X, et al. Macrophages in epididymal adipose tissue secrete osteopontin to regulate bone homeostasis [J]. Nat Commun, 2022, 13(1): 427.
[173] ROCHIRA V, CARANI C. Aromatase deficiency in men: a clinical perspective [J]. Nature Reviews Endocrinology, 2009, 5(10): 559-68.
[174] STREICHER C, HEYNY A, ANDRUKHOVA O, et al. Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells [J]. Scientific Reports, 2017, 7(1): 6460.
[175] RUBITSCHUNG K, SHERWOOD A, KAPADIA R, et al. Aromatase deficiency in transplanted bone marrow cells improves vertebral trabecular bone quantity, connectivity, and mineralization and decreases cortical porosity in murine bone marrow transplant recipients [J]. PLoS One, 2024, 19(2): e0296390.
[176] LESTER J, COLEMAN R. Bone loss and the aromatase inhibitors [J]. British Journal of Cancer, 2005, 93(1): S16-S22.
[177] 赵萍, 王涛, 侯传云, et al. 绝经后女性血脂水平与骨密度的相关性研究 [J]. 蚌埠医学院学报, 2022, 47(09): 1206-9+13.
[178] BONE H G, WAGMAN R B, BRANDI M L, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension [J]. Lancet Diabetes Endocrinol, 2017, 5(7): 513-23.
[179] CHOTIYARNWONG P, MCCLOSKEY E V. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment [J]. Nat Rev Endocrinol, 2020, 16(8): 437 -47.
[180] LIU X, GU Y, KUMAR S, et al. Oxylipin-PPARγ-initiated adipocyte senescence propagates secondary senescence in the bone marrow [J]. Cell Metab, 2023, 35(4): 667-84.e6.
[181] HAUNER H, ENTENMANN G, WABITSCH M, et al. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium [J]. J Clin Invest, 1989, 84(5): 1663 -70.
[182] OTHONOS N, POFI R, ARVANITI A, et al. 11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial [J]. Nat Commun, 2023, 14(1): 1025.
[183] KLEY M, MOSER S O, WINTER D V, et al. In vitro methods to assess 11 β-hydroxysteroid dehydrogenase type 2 activity [J]. Methods Enzymol, 2023, 689: 167 -200.
[184] XU Z, LIU D, LIU D, et al. Equisetin is an anti-obesity candidate through targeting 11β-HSD1 [J]. Acta Pharm Sin B, 2022, 12(5): 2358-73.
[185] PENG K, PAN Y, LI J, et al. 11β-Hydroxysteroid Dehydrogenase Type 1(11β-HSD1) mediates insulin resistance through JNK activation in adipocytes [J]. Scientific Reports, 2016, 6(1): 37160.
[186] COOPER M S, STEWART P M. 11β-Hydroxysteroid Dehydrogenase Type 1 and Its Role in the Hypothalamus-Pituitary-Adrenal Axis, Metabolic Syndrome, and Inflammation [J]. The Journal of Clinical Endocrinology & Metabolism, 2009, 94(12): 4645-54.
[187] STOMBY A, ANDREW R, WALKER B R, et al. Tissue-specific dysregulation of cortisol regeneration by 11βHSD1 in obesity: has it promised too much? [J]. Diabetologia, 2014, 57(6): 1100-10.
[188] LI H, HU S, WU R, et al. 11β-Hydroxysteroid Dehydrogenase Type 1 Facilitates Osteoporosis by Turning on Osteoclastogenesis through Hippo Signaling [J]. Int J Biol Sci, 2023, 19(11): 3628-39.
[189] FENTON C G, DOIG C L, FAREED S, et al. 11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy [J]. Arthritis Res Ther, 2019, 21(1): 188.
[190] MARTIN C S, COOPER M S, HARDY R S. Endogenous Glucocorticoid Metabolism in Bone: Friend or Foe [J]. Front Endocrinol (Lausanne), 2021, 12: 733611.
[191] OTHONOS N, POFI R, ARVANITI A, et al. 11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial [J]. Nat Commun, 2023, 14(1): 1025.
[192] GREGORY S, HILL D, GREY B, et al. 11β-hydroxysteroid dehydrogenase type 1 inhibitor use in human disease-a systematic review and narrative synthesis [J]. Metabolism, 2020, 108: 154246.
[193] GU P, PU B, XIN Q, et al. The metabolic score of insulin resistance is positively correlated with bone mineral density in postmenopausal patients with type 2 diabetes mellitus [J]. Scientific Reports, 2023, 13(1): 8796.
[194] WIEBE N, YE F, CRUMLEY E T, et al. Temporal Associations Among Body Mass Index, Fasting Insulin, and Systemic Inflammation: A Systematic Review and Meta -analysis [J]. JAMA Netw Open, 2021, 4(3): e211263.
[195] BILHA S C, LEUSTEAN L, PREDA C, et al. Bone mineral density predictors in long standing type 1 and type 2 diabetes mellitus [J]. BMC Endocrine Disorders, 2021, 21(1): 156.
[196] SANCHES C P, VIANNA A G D, BARRETO F D C. The impact of type 2 diabetes on bone metabolism [J]. Diabetology & Metabolic Syndrome, 2017, 9(1): 85.
[197] ALHUZAIM O N, LEWIS E J H, LOVBLOM L E, et al. Bone mineral density in patients with longstanding type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes [J]. J Diabetes Complications, 2019, 33(11): 107324.
[198] WINTERS S J, GOGINENI J, KAREGAR M, et al. Sex Hormone-Binding Globulin Gene Expression and Insulin Resistance [J]. The Journal of Clinical Endocrinology & Metabolism, 2014, 99(12): E2780-E8.
[199] LIANG B, BURLEY G, LIN S, et al. Osteoporosis pathogenesis and treatment: existing and emerging avenues [J]. Cellular & Molecular Biology Letters, 2022, 27(1): 72.
[200] TAUBMANN J, KRISHNACOUMAR B, BöHM C, et al. Metabolic reprogramming of osteoclasts represents a therapeutic target during the treatment of osteoporosis [J]. Scientific Reports, 2020, 10(1): 21020.
[201] DEMAMBRO V E, KAWAI M, CLEMENS T L, et al. A novel spontaneous mutation of Irs1 in mice results in hyperinsulinemia, reduced growth, low bone mass and impaired adipogenesis [J]. J Endocrinol, 2010, 204(3): 241-53.
[202] FULZELE K, RIDDLE R C, DIGIROLAMO D J, et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition [J]. Cell, 2010, 142(2): 309-19.
[203] OGATA N, CHIKAZU D, KUBOTA N, et al. Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover [J]. J Clin Invest, 2000, 105(7): 935 -43.
[204] AKUNE T, OGATA N, HOSHI K, et al. Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts [J]. J Cell Biol, 2002, 159(1): 147-56.
[205] REDA T K, GELIEBTER A, PI-SUNYER F X. Amylin, food intake, and obesity [J]. Obes Res, 2002, 10(10): 1087-91.
[206] HAY D L, CHEN S, LUTZ T A, et al. Amylin: Pharmacology, Physiology, and Clinical Potential [J]. Pharmacol Rev, 2015, 67(3): 564-600.
[207] XIE J, GUO J, KANWAL Z, et al. Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations [J]. Int J Endocrinol, 2020, 2020: 3236828.
[208] CORNISH J, NAOT D. Amylin and adrenomedullin: novel regulators of bone growth [J]. Curr Pharm Des, 2002, 8(23): 2009-21.
[209] CORNISH J, CALLON K E, BAVA U, et al. Preptin, another peptide product of the pancreatic beta-cell, is osteogenic in vitro and in vivo [J]. Am J Physiol Endocrinol Metab, 2007, 292(1): E117-22.
[210] YANG G, LI L, CHEN W, et al. Circulating preptin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects [J]. Ann Med, 2009, 41(1): 52 -6.
[211] LEE K S, LEE J, KIM H K, et al. Extracellular vesicles from adipose tissue -derived stem cells alleviate osteoporosis through osteoprotegerin and miR-21-5p [J]. J Extracell Vesicles, 2021, 10(12): e12152.
[212] DAI B, XU J, LI X, et al. Macrophages in epididymal adipose tissue secrete osteopontin to regulate bone homeostasis [J]. Nat Commun, 2022, 13(1): 427.
[213] LIU P, JI Y, YUEN T, et al. Blocking FSH induces thermogenic adipose tissue and reduces body fat [J]. Nature, 2017, 546(7656): 107-12.
[214] ZHU L-L, BLAIR H, CAO J, et al. Blocking antibody to the β-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis [J]. Proc Natl Acad Sci U S A, 2012, 109(36): 14574-9.
[215] ZOU W, ROHATGI N, BRESTOFF J R, et al. Ablation of Fat Cells in Adult Mice Induces Massive Bone Gain [J]. Cell Metab, 2020, 32(5).
[216] KERSTEN S. Peroxisome proliferator activated receptors and obesity [J]. Eur J Pharmacol, 2002, 440(2-3): 223-34.
[217] BAIN D L, HENEGHAN A F, CONNAGHAN-JONES K D, et al. Nuclear receptor structure: implications for function [J]. Annu Rev Physiol, 2007, 69: 201 -20.
[218] CHANDRA V, HUANG P, HAMURO Y, et al. Structure of the intact PPAR-gamma RXR- nuclear receptor complex on DNA [J]. Nature, 2008, 456(7220): 350 -6.
[219] PETERS J M, SHAH Y M, GONZALEZ F J. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention [J]. Nature Reviews Cancer, 2012, 12(3): 181-95.
[220] LIN Y, WANG Y, LI P F. PPARα: An emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases [J]. Front Endocrinol (Lausanne), 2022, 13: 1074911.
[221] BASTIE C, LUQUET S, HOLST D, et al. Alterations of peroxisome proliferatoractivated receptor delta activity affect fatty acid-controlled adipose differentiation [J]. J Biol Chem, 2000, 275(49): 38768-73.
[222] LEE J-E, GE K. Transcriptional and epigenetic regulation of PPARγ expression during adipogenesis [J]. Cell & Bioscience, 2014, 4(1): 29.
[223] TANG P, VIRTUE S, GOIE J Y G, et al. Regulation of adipogenic differentiation and adipose tissue inflammation by interferon regulatory factor 3 [J]. Cell Death & Differentiation, 2021, 28(11): 3022-35.
[224] AHMADIAN M, SUH J M, HAH N, et al. PPARγ signaling and metabolism: the good, the bad and the future [J]. Nature Medicine, 2013, 19(5): 557-66.
[225] KERSTEN S, SEYDOUX J, PETERS J M, et al. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting [J]. J Clin Invest, 1999, 103(11): 1489-98.
[226] SHIMOIKE T, YANASE T, UMEDA F, et al. Subcutaneous or visceral adipose tissue expression of the PPARγ gene is not altered in the fatty (fafa) Zucker rat [J]. Metabolism, 1998, 47(12): 1494-8.
[227] HU W, JIANG C, KIM M, et al. Isoform-specific functions of PPARγ in gene regulation and metabolism [J]. Genes Dev, 2022, 36(5-6): 300-12.
[228] MONTAIGNE D, BUTRUILLE L, STAELS B. PPAR control of metabolism and cardiovascular functions [J]. Nature Reviews Cardiology, 2021, 18(12): 809 -23.
[229] LEBOVITZ H E. Thiazolidinediones: the Forgotten Diabetes Medications [J]. Curr Diab Rep, 2019, 19(12): 151.
[230] LEE J E, SCHMIDT H, LAI B, et al. Transcriptional and Epigenomic Regulation of Adipogenesis [J]. Mol Cell Biol, 2019, 39(11).
[231] CRISTANCHO A G, LAZAR M A. Forming functional fat: a growing understanding of adipocyte differentiation [J]. Nat Rev Mol Cell Biol, 2011, 12(11): 722 -34.
[232] HAUSMAN G J, POULOS S P, PRINGLE T D, et al. The influence of thiazolidinediones on adipogenesis in vitro and in vivo: potential modifiers of intramuscular adipose tissue deposition in meat animals [J]. J Anim Sci, 2008, 86(14 Suppl): E236-43.
[233] AUWERX J. PPARgamma, the ultimate thrifty gene [J]. Diabetologia, 1999, 42(9): 1033-49.
[234] LIN Z, TIAN H, LAM K S, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice [J]. Cell Metab, 2013, 17(5): 779-89.
[235] ITOH T, FAIRALL L, AMIN K, et al. Structural basis for the activation of PPARγ by oxidized fatty acids [J]. Nature Structural & Molecular Biology, 2008, 15(9): 924 -31.
[236] QUARANTA A, REVOL-CAVALIER J, WHEELOCK C E. The octadecanoids: an emerging class of lipid mediators [J]. Biochem Soc Trans, 2022, 50(6): 1569 -82.
[237] LECKA-CZERNIK B, MOERMAN E J, GRANT D F, et al. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation [J]. Endocrinology, 2002, 143(6): 2376 -84.
[238] GARIN-SHKOLNIK T, RUDICH A, HOTAMISLIGIL G S, et al. FABP4 attenuates PPARγ and adipogenesis and is inversely correlated with PPARγ in adipose tissues [J]. Diabetes, 2014, 63(3): 900-11.
[239] TONTONOZ P, GRAVES R A, BUDAVARI A I, et al. Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha [J]. Nucleic Acids Res, 1994, 22(25): 5628-34.
[240] TONTONOZ P, HU E, SPIEGELMAN B M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor [J]. Cell, 1994, 79(7): 1147-56.
[241] CAO Y, CHEN Y, MIAO K, et al. PPARγ As a Potential Target for Adipogenesis Induced by Fine Particulate Matter in 3T3-L1 Preadipocytes [J]. Environ Sci Technol, 2023, 57(20): 7684-97.
[242] ROSEN E D, SARRAF P, TROY A E, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro [J]. Mol Cell, 1999, 4(4): 611 -7.
[243] BARAK Y, NELSON M C, ONG E S, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development [J]. Mol Cell, 1999, 4(4): 585 -95.
[244] KUBOTA N, TERAUCHI Y, MIKI H, et al. PPAR gamma mediates high-fat dietinduced adipocyte hypertrophy and insulin resistance [J]. Mol Cell, 1999, 4(4): 597 -609.
[245] DESVERGNE B, WAHLI W. Peroxisome proliferator-activated receptors: nuclear control of metabolism [J]. Endocr Rev, 1999, 20(5): 649-88.
[246] VIDAL-PUIG A, JIMENEZ-LIñAN M, LOWELL B B, et al. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents [J]. J Clin Invest, 1996, 97(11): 2553-61.
[247] VIDAL-PUIG A J, CONSIDINE R V, JIMENEZ-LIñAN M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids [J]. J Clin Invest, 1997, 99(10): 2416-22.
[248] ANUSREE S S, SINDHU G, PREETHA RANI M R, et al. Insulin resistance in 3T3-L1 adipocytes by TNF-α is improved by punicic acid through upregulation of insulin signalling pathway and endocrine function, and downregulation of proinflammatory cytokines [J]. Biochimie, 2018, 146: 79-86.
[249] PEI H, YAO Y, YANG Y, et al. Krüppel-like factor KLF9 regulates PPARγ transactivation at the middle stage of adipogenesis [J]. Cell Death & Differentiation, 2011, 18(2): 315-27.
[250] GAO W, GAO Z, PU S, et al. The Underlying Regulated Mechanisms of Adipose Differentiation and Apoptosis of Breast Cells after Weaning [J]. Curr Protein Pept Sci, 2019, 20(7): 696-704.
[251] KIM J B, WRIGHT H M, WRIGHT M, et al. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand [J]. Proc Natl Acad Sci U S A, 1998, 95(8): 4333-7.
[252] FAJAS L, SCHOONJANS K, GELMAN L, et al. Regulation of peroxisome proliferator-activated receptor γ expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism [J]. Mol Cell Biol, 1999, 19(8): 5495-503.
[253] REUSCH J E, COLTON L A, KLEMM D J. CREB activation induces adipogenesis in 3T3-L1 cells [J]. Mol Cell Biol, 2000, 20(3): 1008-20.
[254] YAO D, ZHAO X, ZHAO S, et al. Characterization of the fatty acid binding protein 3 (FABP3) promoter and its transcriptional regulation by cAMP response element binding protein 1 (CREB1) in goat mammary epithelial cells [J]. Anim Biotechnol, 2023, 34(6): 1960-7.
[255] GUPTA R K, ARANY Z, SEALE P, et al. Transcriptional control of preadipocyte determination by Zfp423 [J]. Nature, 2010, 464(7288): 619-23.
[256] SHAO M, ZHANG Q, TRUONG A, et al. ZFP423 controls EBF2 coactivator recruitment and PPARγ occupancy to determine the thermogenic plasticity of adipocytes [J]. Genes Dev, 2021, 35(21-22): 1461-74.
[257] SHANG J, BRUST R, MOSURE S A, et al. Cooperative cobinding of synthetic and natural ligands to the nuclear receptor PPARγ [J]. Elife, 2018, 7.
[258] NELSON D L, COX M M. Lehninger Principles of Biochemistry. 6. izdanje [J]. H Freeman and Company, New York, 2013: 226-8.
[259] FALOMIR-LOCKHART L J, CAVAZZUTTI G F, GIMéNEZ E, et al. Fatty Acid Signaling Mechanisms in Neural Cells: Fatty Acid Receptors [J]. Front Cell Neurosci, 2019, 13: 162.
[260] KIM M H, SEONG J B, HUH J W, et al. Peroxiredoxin 5 ameliorates obesity -induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP activated protein kinase signaling [J]. Redox Biol, 2020, 28: 101315.
[261] ALBERTS A W, STRAUSS A W, HENNESSY S, et al. Regulation of synthesis of hepatic fatty acid synthetase: binding of fatty acid synthetase antibodies to polysomes [J]. Proc Natl Acad Sci U S A, 1975, 72(10): 3956-60.
[262] ASTURIAS F J, CHADICK J Z, CHEUNG I K, et al. Structure and molecular organization of mammalian fatty acid synthase [J]. Nat Struct Mol Biol, 2005, 12(3): 225-32.
[263] CHAKRAVARTY B, GU Z, CHIRALA S S, et al. Human fatty acid synthase: structure and substrate selectivity of the thioesterase domain [J]. Proc Natl Acad Sci U S A, 2004, 101(44): 15567-72.
[264] SMITH S, WITKOWSKI A, JOSHI A K. Structural and functional organization of the animal fatty acid synthase [J]. Prog Lipid Res, 2003, 42(4): 289 -317.
[265] LIN H P, CHENG Z L, HE R Y, et al. Destabilization of Fatty Acid Synthase by Acetylation Inhibits De Novo Lipogenesis and Tumor Cell Growth [J]. Cancer Res, 2016, 76(23): 6924-36.
[266] SONG Z, XIAOLI A M, YANG F. Regulation and Metabolic Significance of De Novo Lipogenesis in Adipose Tissues [J]. Nutrients, 2018, 10(10).
[267] SCHWEIZER M, RODER K, ZHANG L, et al. Transcription factors acting on the promoter of the rat fatty acid synthase gene [J]. Biochem Soc Trans, 2002, 30(Pt 6): 1070-2.
[268] FURUTA E, PAI S K, ZHAN R, et al. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein -1 [J]. Cancer Res, 2008, 68(4): 1003-11.
[269] JUMP D B, TRIPATHY S, DEPNER C M. Fatty acid-regulated transcription factors in the liver [J]. Annu Rev Nutr, 2013, 33: 249-69.
[270] PAIVA P, MEDINA F E, VIEGAS M, et al. Animal Fatty Acid Synthase: A Chemical Nanofactory [J]. Chem Rev, 2021, 121(15): 9502-53.
[271] ROWLAND L A, GUILHERME A, HENRIQUES F, et al. De novo lipogenesis fuels adipocyte autophagosome and lysosome membrane dynamics [J]. Nat Commun, 2023, 14(1): 1362.
[272] TSUJIHATA Y, ITO R, SUZUKI M, et al. TAK-875, an orally available G proteincoupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose -dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats [J]. J Pharmacol Exp Ther, 2011, 339(1): 228-37.
[273] CAO H, GERHOLD K, MAYERS J R, et al. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism [J]. Cell, 2008, 134(6): 933-44.
[274] CALDER P C. Functional Roles of Fatty Acids and Their Effects on Human Health [J]. JPEN J Parenter Enteral Nutr, 2015, 39(1 Suppl): 18s-32s.
[275] GHOSH A, GAO L, THAKUR A, et al. Role of free fatty acids in endothelial dysfunction [J]. J Biomed Sci, 2017, 24(1): 50.
[276] STORCH J, THUMSER A E A. The fatty acid transport function of fatty acid-binding proteins [J]. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2000, 1486(1): 28-44.
[277] ZHUANG L, LI C, CHEN Q, et al. Fatty acid-binding protein 3 contributes to ischemic heart injury by regulating cardiac myocyte apoptosis and MAPK pathways [J]. Am J Physiol Heart Circ Physiol, 2019, 316(5): H971-h84.
[278] FURUHASHI M. Fatty Acid-Binding Protein 4 in Cardiovascular and Metabolic Diseases [J]. J Atheroscler Thromb, 2019, 26(3): 216-32.
[279] SMATHERS R L, PETERSEN D R. The human fatty acid-binding protein family: evolutionary divergences and functions [J]. Hum Genomics, 2011, 5(3): 170 -91.
[280] ZIMMERMAN A W, VEERKAMP J H. New insights into the structure and function of fatty acid-binding proteins [J]. Cell Mol Life Sci, 2002, 59(7): 1096-116.
[281] SENGA S, KOBAYASHI N, KAWAGUCHI K, et al. Fatty acid-binding protein 5 (FABP5) promotes lipolysis of lipid droplets, de novo fatty acid (FA) synthesis and activation of nuclear factor-kappa B (NF-κB) signaling in cancer cells [J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2018, 1863(9): 1057-67.
[282] GAJDA A M, STORCH J. Enterocyte fatty acid-binding proteins (FABPs): different functions of liver and intestinal FABPs in the intestine [J]. Prostaglandins Leukot Essent Fatty Acids, 2015, 93: 9-16.
[283] ZHANG Y, SUN Y, RAO E, et al. Fatty acid-binding protein E-FABP restricts tumor growth by promoting IFN-β responses in tumor-associated macrophages [J]. Cancer Res, 2014, 74(11): 2986-98.
[284] HOTAMISLIGIL G S, BERNLOHR D A. Metabolic functions of FABPs--mechanisms and therapeutic implications [J]. Nat Rev Endocrinol, 2015, 11(10): 592 -605.
[285] QUEIPO-ORTUñO M I, ESCOTé X, CEPERUELO-MALLAFRé V, et al. FABP4 dynamics in obesity: discrepancies in adipose tissue and liver expression regarding circulating plasma levels [J]. PLoS One, 2012, 7(11): e48605.
[286] FURUHASHI M, SAITOH S, SHIMAMOTO K, et al. Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases [J]. Clin Med Insights Cardiol, 2014, 8(Suppl 3): 23 -33.
[287] ARAGONèS G, SAAVEDRA P, HERAS M, et al. Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells [J]. Cardiovasc Diabetol, 2012, 11: 72.
[288] RODRíGUEZ-CALVO R, GIRONA J, RODRíGUEZ M, et al. Fatty acid binding protein 4 (FABP4) as a potential biomarker reflecting myocardial lipid storage in type 2 diabetes [J]. Metabolism, 2019, 96: 12-21.
[289] BURAK M F, INOUYE K E, WHITE A, et al. Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes [J]. Sci Transl Med, 2015, 7(319): 319ra205.
[290] SYAMSUNARNO M R, ISO T, HANAOKA H, et al. A critical role of fatty acid binding protein 4 and 5 (FABP4/5) in the systemic response to fasting [J]. PLoS One, 2013, 8(11): e79386.
[291] SO S W, NIXON J P, BERNLOHR D A, et al. RNAseq Analysis of FABP4 Knockout Mouse Hippocampal Transcriptome Suggests a Role for WNT/β-Catenin in Preventing Obesity-Induced Cognitive Impairment [J]. Int J Mol Sci, 2023, 24(4).
[292] YAO F, JIANG D D, GUO W H, et al. FABP4 inhibitor attenuates inflammation and endoplasmic reticulum stress of islet in leptin receptor knockout rats [J]. Eur Rev Med Pharmacol Sci, 2020, 24(24): 12808-20.
[293] BOSS M, KEMMERER M, BRüNE B, et al. FABP4 inhibition suppresses PPARγ activity and VLDL-induced foam cell formation in IL-4-polarized human macrophages [J]. Atherosclerosis, 2015, 240(2): 424-30.
[294] LV Q, WANG G, ZHANG Y, et al. FABP5 regulates the proliferation of clear cell renal cell carcinoma cells via the PI3K/AKT signaling pathway [J]. Int J Oncol, 2019, 54(4): 1221-32.
[295] UEHARA H, TAKAHASHI T, OHA M, et al. Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression [J]. Int J Cancer, 2014, 135(11): 2558-68.
[296] YANG A, ZHANG H, SUN Y, et al. Modulation of FABP4 hypomethylation by DNMT1 and its inverse interaction with miR-148a/152 in the placenta of preeclamptic rats and HTR-8 cells [J]. Placenta, 2016, 46: 49-62.
[297] TIAN W, ZHANG W, ZHANG Y, et al. FABP4 promotes invasion and metastasis of colon cancer by regulating fatty acid transport [J]. Cancer Cell Int, 2020, 20: 512.
[298] GHARPURE K M, PRADEEP S, SANS M, et al. FABP4 as a key determinant of metastatic potential of ovarian cancer [J]. Nat Commun, 2018, 9(1): 2923.
[299] LI H Y, LV B B, BI Y H. FABP4 accelerates glioblastoma cell growth and metastasis through Wnt10b signalling [J]. Eur Rev Med Pharmacol Sci, 2018, 22(22): 7807 -18.
[300] CAO H, YAN Q, WANG D, et al. Focal adhesion protein Kindlin-2 regulates bone homeostasis in mice [J]. Bone Research, 2020, 8: 2.
[301] JOBARD F, BOUADJAR B, CAUX F, et al. Identification of mutations in a new gene encoding a FERM family protein with a pleckstrin homology domain in Kindler syndrome [J]. Human Molecular Genetics, 2003, 12(8): 925-35.
[302] SIEGEL D H, ASHTON G H S, PENAGOS H G, et al. Loss of kindlin-1, a human homolog of the Caenorhabditis elegans actin-extracellular-matrix linker protein UNC-112, causes Kindler syndrome [J]. Am J Hum Genet, 2003, 73(1): 174 -87.
[303] SVENSSON L, HOWARTH K, MCDOWALL A, et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation [J]. Nat Med, 2009, 15(3): 306-12.
[304] MOSER M, NIESWANDT B, USSAR S, et al. Kindlin-3 is essential for integrin activation and platelet aggregation [J]. Nat Med, 2008, 14(3): 325 -30.
[305] SCHMIDT S, NAKCHBANDI I, RUPPERT R, et al. Kindlin-3-mediated signaling from multiple integrin classes is required for osteoclast-mediated bone resorption [J]. J Cell Biol, 2011, 192(5): 883-97.
[306] MALININ N L, ZHANG L, CHOI J, et al. A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans [J]. Nat Med, 2009, 15(3): 313 -8.
[307] AZORIN P, BONIN F, MOUKACHAR A, et al. Distinct expression profiles and functions of Kindlins in breast cancer [J]. J Exp Clin Cancer Res, 2018, 37(1): 281.
[308] ROGNONI E, WIDMAIER M, JAKOBSON M, et al. Kindlin-1 controls Wnt and TGF-β availability to regulate cutaneous stem cell proliferation [J]. Nat Med, 2014, 20(4): 350-9.
[309] USSAR S, WANG H V, LINDER S, et al. The Kindlins: subcellular localization and expression during murine development [J]. Exp Cell Res, 2006, 312(16): 3142 -51.
[310] MOSER M, NIESWANDT B, USSAR S, et al. Kindlin-3 is essential for integrin activation and platelet aggregation [J]. Nat Med, 2008, 14(3): 325 -30.
[311] KUIJPERS T W, VAN DE VIJVER E, WETERMAN M A, et al. LAD-1/variant syndrome is caused by mutations in FERMT3 [J]. Blood, 2009, 113(19): 4740 -6.
[312] DOWLING J J, GIBBS E, RUSSELL M, et al. Kindlin-2 is an essential component of intercalated discs and is required for vertebrate cardiac structure and function [J]. Circ Res, 2008, 102(4): 423-31.
[313] MONTANEZ E, USSAR S, SCHIFFERER M, et al. Kindlin-2 controls bidirectional signaling of integrins [J]. Genes Dev, 2008, 22(10): 1325-30.
[314] LARJAVA H, PLOW E F, WU C. Kindlins: essential regulators of integrin signalling and cell-matrix adhesion [J]. EMBO Rep, 2008, 9(12): 1203-8.
[315] MACKINNON A C, QADOTA H, NORMAN K R, et al. C. elegans PAT-4/ILK functions as an adaptor protein within integrin adhesion complexes [J]. Curr Biol, 2002, 12(10): 787-97.
[316] TU Y, WU S, SHI X, et al. Migfilin and Mig-2 link focal adhesions to filamin and the actin cytoskeleton and function in cell shape modulation [J]. Cell, 2003, 113(1): 37 -47.
[317] MONTANEZ E, USSAR S, SCHIFFERER M, et al. Kindlin-2 controls bidirectional signaling of integrins [J]. Genes Dev, 2008, 22(10): 1325-30.
[318] WU C. Migfilin and its binding partners: from cell biology to human diseases [J]. J Cell Sci, 2005, 118(Pt 4): 659-64.
[319] SHI X, MA Y Q, TU Y, et al. The MIG-2/integrin interaction strengthens cell-matrix adhesion and modulates cell motility [J]. J Biol Chem, 2007, 282(28): 20455 -66.
[320] KLOEKER S, MAJOR M B, CALDERWOOD D A, et al. The Kindler syndrome protein is regulated by transforming growth factor-beta and involved in integrinmediated adhesion [J]. J Biol Chem, 2004, 279(8): 6824-33.
[321] ROGNONI E, RUPPERT R, FäSSLER R. The kindlin family: functions, signaling properties and implications for human disease [J]. J Cell Sci, 2016, 129(1): 17 -27.
[322] CALDERWOOD D A, CAMPBELL I D, CRITCHLEY D R. Talins and kindlins: partners in integrin-mediated adhesion [J]. Nat Rev Mol Cell Biol, 2013, 14(8): 503-17.
[323] BöTTCHER R T, VEELDERS M, ROMBAUT P, et al. Kindlin-2 recruits paxillin and Arp2/3 to promote membrane protrusions during initial cell spreading [J]. J Cell Biol, 2017, 216(11): 3785-98.
[324] WEI X, WANG X, ZHAN J, et al. Smurf1 inhibits integrin activation by controlling Kindlin-2 ubiquitination and degradation [J]. J Cell Biol, 2017, 216(5): 1455 -71.
[325] LI H, DENG Y, SUN K, et al. Structural basis of kindlin-mediated integrin recognition and activation [J]. Proc Natl Acad Sci U S A, 2017, 114(35): 9349 -54.
[326] HIRBAWI J, BIALKOWSKA K, BLEDZKA K M, et al. The extreme C-terminal region of kindlin-2 is critical to its regulation of integrin activation [J]. J Biol Chem, 2017, 292(34): 14258-69.
[327] LEE P L, TANG Y, LI H, et al. Raptor/mTORC1 loss in adipocytes causes progressive lipodystrophy and fatty liver disease [J]. Mol Metab, 2016, 5(6): 422 -32.
[328] TAN X, BEHARI J, CIEPLY B, et al. Conditional deletion of beta -catenin reveals its role in liver growth and regeneration [J]. Gastroenterology, 2006, 131(5): 1561 -72.
[329] KAWAI M, DEVLIN M J, ROSEN C J. Fat targets for skeletal health [J]. Nat Rev Rheumatol, 2009, 5(7): 365-72.
[330] XIA B, CAI G H, YANG H, et al. Adipose tissue deficiency of hormone -sensitive lipase causes fatty liver in mice [J]. PLoS Genet, 2017, 13(12): e1007110.
[331] WANG F, MULLICAN S E, DISPIRITO J R, et al. Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPARγ [J]. Proc Natl Acad Sci U S A, 2013, 110(46): 18656-61.
[332] QIANG G, WHANG KONG H, XU S, et al. Lipodystrophy and severe metabolic dysfunction in mice with adipose tissue-specific insulin receptor ablation [J]. Mol Metab, 2016, 5(7): 480-90.
[333] SOFTIC S, BOUCHER J, SOLHEIM M H, et al. Lipodystrophy Due to Adipose Tissue-Specific Insulin Receptor Knockout Results in Progressive NAFLD [J]. Diabetes, 2016, 65(8): 2187-200.
[334] SHEARIN A L, MONKS B R, SEALE P, et al. Lack of AKT in adipocytes causes severe lipodystrophy [J]. Mol Metab, 2016, 5(7): 472-9.
[335] WOJTANIK K M, EDGEMON K, VISWANADHA S, et al. The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan -type familial partial lipodystrophy mutation [J]. J Lipid Res, 2009, 50(6): 1068 -79.
[336] MISRA A, GARG A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature [J]. Medicine (Baltimore), 2003, 82(2): 129-46.
[337] BARTELT A, BRUNS O T, REIMER R, et al. Brown adipose tissue activity controls triglyceride clearance [J]. Nat Med, 2011, 17(2): 200-5.
[338] GAO H, GUO Y, YAN Q, et al. Lipoatrophy and metabolic disturbance in mice with adipose-specific deletion of kindlin-2 [J]. JCI Insight, 2019, 4(13).
[339] CAO H, YAN Q, WANG D, et al. Focal adhesion protein Kindlin-2 regulates bone homeostasis in mice [J]. Bone research, 2020, 8(1): 2.
[340] FU X, ZHOU B, YAN Q, et al. Kindlin-2 regulates skeletal homeostasis by modulating PTH1R in mice [J]. Signal Transduct Target Ther, 2020, 5(1): 297.
[341] BRUNNER M, MILLON-FRéMILLON A, CHEVALIER G, et al. Osteoblast mineralization requires beta1 integrin/ICAP-1-dependent fibronectin deposition [J]. J Cell Biol, 2011, 194(2): 307-22.
[342] JUNG G Y, PARK Y J, HAN J S. Mediation of Rac1 activation by kindlin-2: an essential function in osteoblast adhesion, spreading, and proliferation [J]. J Cell Biochem, 2011, 112(9): 2541-8.
[343] GUO L, CAI T, CHEN K, et al. Kindlin-2 regulates mesenchymal stem cell differentiation through control of YAP1/TAZ [J]. J Cell Biol, 2018, 217(4): 1431 -51.
[344] QIN L, FU X, MA J, et al. Kindlin-2 mediates mechanotransduction in bone by regulating expression of Sclerostin in osteocytes [J]. Commun Biol, 2021, 4(1): 402.
[345] CHEN S, WU X, LAI Y, et al. Kindlin-2 inhibits Nlrp3 inflammasome activation in nucleus pulposus to maintain homeostasis of the intervertebral disc [J]. Bone Res, 2022, 10(1): 5.
[346] WU C, JIAO H, LAI Y, et al. Kindlin-2 controls TGF-β signalling and Sox9 expression to regulate chondrogenesis [J]. Nat Commun, 2015, 6: 7531.
[347] WU X, QU M, GONG W, et al. Kindlin-2 deletion in osteoprogenitors causes severe chondrodysplasia and low-turnover osteopenia in mice [J]. J Orthop Translat, 2022, 32: 41-8.
[348] WU X, LAI Y, CHEN S, et al. Kindlin-2 preserves integrity of the articular cartilage to protect against osteoarthritis [J]. Nat Aging, 2022, 2(4): 332 -47.
[349] LAI Y, ZHENG W, QU M, et al. Kindlin-2 loss in condylar chondrocytes causes spontaneous osteoarthritic lesions in the temporomandibular joint in mice [J]. Int J Oral Sci, 2022, 14(1): 33.
[350] GAO H, ZHONG Y, ZHOU L, et al. Kindlin-2 inhibits TNF/NF-κB-Caspase 8 pathway in hepatocytes to maintain liver development and function [J]. Elife, 2023, 12.
[351] ZHONG Y, ZHOU L, WANG H, et al. Correction: Kindlin-2 maintains liver homeostasis by regulating GSTP1-OPN-mediated oxidative stress and inflammation in mice [J]. J Biol Chem, 2024, 300(3): 105738.
[352] GAO H, ZHOU L, ZHONG Y, et al. Kindlin-2 haploinsufficiency protects against fatty liver by targeting Foxo1 in mice [J]. Nat Commun, 2022, 13(1): 1025.
[353] YU J, HU Y, GAO Y, et al. Kindlin-2 regulates hepatic stellate cells activation and liver fibrogenesis [J]. Cell Death Discov, 2018, 4: 34.
[354] ZHANG J, REN Y, BI J, et al. Involvement of kindlin-2 in irisin's protection against ischaemia reperfusion-induced liver injury in high-fat diet-fed mice [J]. J Cell Mol Med, 2020, 24(22): 13081-92.
[355] ZHU K, LAI Y, CAO H, et al. Kindlin-2 modulates MafA and β-catenin expression to regulate β-cell function and mass in mice [J]. Nat Commun, 2020, 11(1): 484.
[356] RUIZ-OJEDA F J, WANG J, BäCKER T, et al. Active integrins regulate white adipose tissue insulin sensitivity and brown fat thermogenesis [J]. Mol Metab, 2021, 45: 101147.
[357] WU C, JIAO H, LAI Y, et al. Kindlin-2 controls TGF-β signalling and Sox9 expression to regulate chondrogenesis [J]. Nat Commun, 2015, 6: 7531.
[358] LEE K Y, RUSSELL S J, USSAR S, et al. Lessons on conditional gene targeting in mouse adipose tissue [J]. Diabetes, 2013, 62(3): 864-74.
[359] ROWE D W, ADAMS D J, HONG S-H, et al. Screening gene knockout mice for variation in bone mass: analysis by μCT and histomorphometry [J]. Current osteoporosis reports, 2018, 16: 77-94.
[360] WANG Y, YAN Q, ZHAO Y, et al. Focal adhesion proteins Pinch1 and Pinch2 regulate bone homeostasis in mice [J]. JCI Insight, 2019, 4(22).
[361] KONERMANN S, LOTFY P, BRIDEAU N J, et al. Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors [J]. Cell, 2018, 173(3).
[362] HUANG W, LIU X, QUEEN N J, et al. Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver [J]. Mol Ther Methods Clin Dev, 2017, 6: 68-78.
[363] CUMMINGS S R, SAN MARTIN J, MCCLUNG M R, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [J]. N Engl J Med, 2009, 361(8): 756-65.
[364] ORCEL P, FUNCK-BRENTANO T. Medical management following an osteoporotic fracture [J]. Orthop Traumatol Surg Res, 2011, 97(8): 860-9.
[365] CAO J J. Effects of obesity on bone metabolism [J]. J Orthop Surg Res, 2011, 6: 30.
[366] CAO J J, GREGOIRE B R, GAO H. High-fat diet decreases cancellous bone mass but has no effect on cortical bone mass in the tibia in mice [J]. Bone, 2009, 44(6): 1097 -104.
[367] INFANTE M, FABI A, COGNETTI F, et al. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives [J]. J Exp Clin Cancer Res, 2019, 38(1): 12.
[368] LACEY D L, TIMMS E, TAN H L, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation [J]. Cell, 1998, 93(2): 165 -76.
[369] BOYCE B F, XING L. Biology of RANK, RANKL, and osteoprotegerin [J]. Arthritis Res Ther, 2007, 9 Suppl 1(Suppl 1): S1.
[370] HARUYAMA N, CHO A, KULKARNI A B. Overview: engineering transgenic constructs and mice [J]. Curr Protoc Cell Biol, 2009, Chapter 19: Unit 19.0.
[371] BALDUCCI C, FORLONI G. APP transgenic mice: their use and limitations [J]. Neuromolecular Med, 2011, 13(2): 117-37.
[372] 王依姝. 粘附因子 Pinch1/2 对骨稳态的调控作用及机制研究 [D], 2020.
[373] ROWE D W, ADAMS D J, HONG S-H, et al. Screening Gene Knockout Mice for Variation in Bone Mass: Analysis by μCT and Histomorphometry [J]. Curr Osteoporos Rep, 2018, 16(2): 77-94.
[374] BROTTO M, BONEWALD L. Bone and muscle: Interactions beyond mechanical [J]. Bone, 2015, 80: 109-14.
[375] TAGLIAFERRI C, WITTRANT Y, DAVICCO M-J, et al. Muscle and bone, two interconnected tissues [J]. Ageing Res Rev, 2015, 21: 55-70.
[376] HAYASHI M, NAKASHIMA T, YOSHIMURA N, et al. Autoregulation of Osteocyte Sema3A Orchestrates Estrogen Action and Counteracts Bone Aging [J]. Cell Metab, 2019, 29(3).
[377] SZULC P, NAYLOR K, HOYLE N R, et al. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability [J]. Osteoporos Int, 2017, 28(9): 2541-56.
[378] SZULC P. Bone turnover: Biology and assessment tools [J]. Best Pract Res Clin Endocrinol Metab, 2018, 32(5): 725-38.
[379] LEVI B, JAMES A W, NELSON E R, et al. Human adipose-derived stromal cells stimulate autogenous skeletal repair via paracrine Hedgehog signaling with calvarial osteoblasts [J]. Stem Cells Dev, 2011, 20(2): 243-57.
[380] KUROKI Y, SHIOZAWA S, SUGIMOTO T, et al. Constitutive c-fos expression in osteoblastic MC3T3-E1 cells stimulates osteoclast maturation and osteoclastic bone resorption [J]. Clin Exp Immunol, 1994, 95(3): 536-9.
[381] KANG H, YANG K, XIAO L, et al. Osteoblast Hypoxia-Inducible Factor-1α Pathway Activation Restrains Osteoclastogenesis the Interleukin-33-MicroRNA-34a-Notch1 Pathway [J]. Front Immunol, 2017, 8: 1312.
[382] HU K, OLSEN B R. Osteoblast-derived VEGF regulates osteoblast differentiation and bone formation during bone repair [J]. J Clin Invest, 2016, 126(2): 509-26.
[383] ZHONG L, YAO L, TOWER R J, et al. Single cell transcriptomics identifies a unique adipose lineage cell population that regulates bone marrow environment [J]. Elife, 2020, 9.
[384] PROCKOP D J. Marrow stromal cells as stem cells for nonhematopoietic tissues [J]. Science, 1997, 276(5309): 71-4.
[385] YU W, ZHONG L, YAO L, et al. Bone marrow adipogenic lineage precursors promote osteoclastogenesis in bone remodeling and pathologic bone loss [J]. J Clin Invest, 2021, 131(2).
[386] CONG Q, JIA H, BISWAS S, et al. p38α MAPK Regulates Lineage Commitment and OPG Synthesis of Bone Marrow Stromal Cells to Prevent Bone Loss under Physiological and Pathological Conditions [J]. Stem Cell Reports, 2016, 6(4): 566 -78.
[387] BHARADWAZ A, JAYASURIYA A C. Osteogenic differentiation cues of the bone morphogenetic protein-9 (BMP-9) and its recent advances in bone tissue regeneration [J]. Mater Sci Eng C Mater Biol Appl, 2021, 120: 111748.
[388] LAU W L, KALANTAR-ZADEH K. Towards the revival of alkaline phosphatase for the management of bone disease, mortality and hip fractures [J]. Nephrol Dial Transplant, 2014, 29(8): 1450-2.
[389] NAKASHIMA K, ZHOU X, KUNKEL G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation [J]. Cell, 2002, 108(1): 17-29.
[390] LIU Q, LI M, WANG S, et al. Recent Advances of Osterix Transcription Factor in Osteoblast Differentiation and Bone Formation [J]. Front Cell Dev Biol, 2020, 8: 601224.
[391] WANG H, CHEN H, CHERNICK M, et al. Selenomethionine exposure affects chondrogenic differentiation and bone formation in Japanese medaka (Oryzias latipes) [J]. J Hazard Mater, 2020, 387: 121720.
[392] LONG F. Building strong bones: molecular regulation of the osteoblast lineage [J]. Nat Rev Mol Cell Biol, 2011, 13(1): 27-38.
[393] VASIUKOV G, NOVITSKAYA T, ZIJLSTRA A, et al. Myeloid Cell-Derived TGFβ Signaling Regulates ECM Deposition in Mammary Carcinoma via Adenosine -Dependent Mechanisms [J]. Cancer Res, 2020, 80(12): 2628-38.
[394] INGRAM R T, PARK Y K, CLARKE B L, et al. Age- and gender-related changes in the distribution of osteocalcin in the extracellular matrix of normal male and female bone. Possible involvement of osteocalcin in bone remodeling [J]. J Clin Invest, 1994, 93(3): 989-97.
[395] ZHU Y-S, GU Y, JIANG C, et al. Osteonectin regulates the extracellular matrix mineralization of osteoblasts through P38 signaling pathway [J]. J Cell Physiol, 2020, 235(3): 2220-31.
[396] DIRCKX N, MOORER M C, CLEMENS T L, et al. The role of osteoblasts in energy homeostasis [J]. Nature Reviews Endocrinology, 2019, 15(11): 651-65.
[397] PRESTWICH T C, MACDOUGALD O A. Wnt/beta-catenin signaling in adipogenesis and metabolism [J]. Curr Opin Cell Biol, 2007, 19(6): 612-7.
[398] MOSETI D, REGASSA A, KIM W-K. Molecular Regulation of Adipogenesis and Potential Anti-Adipogenic Bioactive Molecules [J]. Int J Mol Sci, 2016, 17(1).
[399] CRISTANCHO A G, LAZAR M A. Forming functional fat: a growing understanding of adipocyte differentiation [J]. Nat Rev Mol Cell Biol, 2011, 12(11): 722 -34.
[400] CHEN X, AYALA I, SHANNON C, et al. The Diabetes Gene and Wnt Pathway Effector TCF7L2 Regulates Adipocyte Development and Function [J]. Diabetes, 2018, 67(4): 554-68.
[401] TAKADA I, KOUZMENKO A P, KATO S. Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis [J]. Nat Rev Rheumatol, 2009, 5(8): 442 -7.
[402] CHEN Q, SHOU P, ZHENG C, et al. Fate decision of mesenchymal stem cells: adipocytes or osteoblasts? [J]. Cell Death Differ, 2016, 23(7): 1128 -39.
[403] TANG Q Q, LANE M D. Adipogenesis: from stem cell to adipocyte [J]. Annu Rev Biochem, 2012, 81: 715-36.
[404] HOTAMISLIGIL G S, BERNLOHR D A. Metabolic functions of FABPs--mechanisms and therapeutic implications [J]. Nature Reviews Endocrinology, 2015, 11(10): 592 -605.
[405] JONES S F, INFANTE J R. Molecular Pathways: Fatty Acid Synthase [J]. Clin Cancer Res, 2015, 21(24): 5434-8.
[406] OTERO M, LAGO R, LAGO F, et al. Signalling pathway involved in nitric oxide synthase type II activation in chondrocytes: synergistic effect of leptin with interleukin-1 [J]. Arthritis Res Ther, 2005, 7(3): R581-R91.
[407] RAMADORI G, FUJIKAWA T, FUKUDA M, et al. SIRT1 deacetylase in POMC neurons is required for homeostatic defenses against diet-induced obesity [J]. Cell Metab, 2010, 12(1): 78-87.
[408] FULZELE K, RIDDLE R C, DIGIROLAMO D J, et al. Insulin Receptor Signaling in Osteoblasts Regulates Postnatal Bone Acquisition and Body Composition [J]. Cell, 2022, 185(4): 746.
[409] LIU C, XIONG Q, LI Q, et al. CHD7 regulates bone-fat balance by suppressing PPAR-γ signaling [J]. Nat Commun, 2022, 13(1): 1989.
[410] BRADLEY C A. Bone: PPARγ controls marrow adiposity [J]. Nat Rev Endocrinol, 2018, 14(1): 3.
[411] REID I R, BALDOCK P A, CORNISH J. Effects of Leptin on the Skeleton [J]. Endocr Rev, 2018, 39(6): 938-59.
[412] UPADHYAY J, FARR O M, MANTZOROS C S. The role of leptin in regulating bone metabolism [J]. Metabolism, 2015, 64(1): 105-13.
[413] JIE Z, XIE Z, XU W, et al. SREBP-2 aggravates breast cancer associated osteolysis by promoting osteoclastogenesis and breast cancer metastasis [J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(1): 115-25.
[414] ZHENG Z G, ZHANG X, ZHOU Y P, et al. Anhydroicaritin, a SREBPs inhibitor, inhibits RANKL-induced osteoclastic differentiation and improves diabetic osteoporosis in STZ-induced mice [J]. Eur J Pharmacol, 2017, 809: 156-62.
[415] ZHOU Y, SHENG Y J, LI C Y, et al. Beneficial effect and mechanism of natural resourced polysaccharides on regulating bone metabolism through intestinal flora: A review [J]. Int J Biol Macromol, 2023, 253(Pt 7): 127428.
[416] LUCAS S, OMATA Y, HOFMANN J, et al. Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss [J]. Nat Commun, 2018, 9(1): 55.
[417] 张钰涵, 梅其炳, 牛银波. 短链脂肪酸调控骨代谢的作用及机制的研究进展 [J]. 微生物学通报, 2021, 48(11): 4306-14.
[418] XI G, SHEN X, ROSEN C J, et al. IRS-1 Functions as a Molecular Scaffold to Coordinate IGF-I/IGFBP-2 Signaling During Osteoblast Differentiation [J]. J Bone Miner Res, 2016, 31(6): 1300-14.
[419] OGATA N, CHIKAZU D, KUBOTA N, et al. Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover [J]. J Clin Invest, 2000, 105(7): 935-43.
[420] DEMAMBRO V E, KAWAI M, CLEMENS T L, et al. A novel spontaneous mutation of Irs1 in mice results in hyperinsulinemia, reduced growth, low bone mass and impaired adipogenesis [J]. J Endocrinol, 2010, 204(3): 241-53.
[421] YAMAGUCHI M, OGATA N, SHINODA Y, et al. Insulin receptor substrate -1 is required for bone anabolic function of parathyroid hormone in mice [J]. Endocrinology, 2005, 146(6): 2620-8.
[422] MALEKZADEH B, TENGVALL P, OHRNELL L O, et al. Effects of locally administered insulin on bone formation in non-diabetic rats [J]. J Biomed Mater Res A, 2013, 101(1): 132-7.
[423] THRAILKILL K, BUNN R C, LUMPKIN C, JR., et al. Loss of insulin receptor in osteoprogenitor cells impairs structural strength of bone [J]. J Diabetes Res, 2014, 2014: 703589.
[424] BARRETT-CONNOR E, KRITZ-SILVERSTEIN D. Does hyperinsulinemia preserve bone? [J]. Diabetes Care, 1996, 19(12): 1388-92.
[425] DONG X, PARK S, LIN X, et al. Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth [J]. J Clin Invest, 2006, 116(1): 101 -14.
[426] WANG N, LI Y, LI Z, et al. IRS-1 targets TAZ to inhibit adipogenesis of rat bone marrow mesenchymal stem cells through PI3K-Akt and MEK-ERK pathways [J]. Eur J Pharmacol, 2019, 849: 11-21.
[427] HAYASHI T, KUBOTA T, MARIKO I, et al. Lack of Brain Insulin Receptor Substrate -1 Causes Growth Retardation, With Decreased Expression of Growth HormoneReleasing Hormone in the Hypothalamus [J]. Diabetes, 2021, 70(8): 1640 -53.
[428] MYERS M G, JR., GRAMMER T C, WANG L M, et al. Insulin receptor substrate -1 mediates phosphatidylinositol 3'-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation [J]. J Biol Chem, 1994, 269(46): 28783-9.
[429] WEI W, WANG X, YANG M, et al. PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss [J]. Cell Metab, 2010, 11(6): 503-16.
[430] ZHANG S, YU M, GUO F, et al. Rosiglitazone alleviates intrahepatic cholestasis induced by α-naphthylisothiocyanate in mice: The role of circulating 15-deoxy-Δ -PGJ and Nogo [J]. Br J Pharmacol, 2020, 177(5): 1041-60.
[431] XI G, SHEN X, ROSEN C J, et al. IRS-1 Functions as a Molecular Scaffold to Coordinate IGF-I/IGFBP-2 Signaling During Osteoblast Differentiation [J]. J Bone Miner Res, 2016, 31(6): 1300-14.
[432] YAMAGUCHI M, OGATA N, SHINODA Y, et al. Insulin receptor substrate -1 is required for bone anabolic function of parathyroid hormone in mice [J]. Endocrinology, 2005, 146(6): 2620-8.
[433] MALEKZADEH B, TENGVALL P, OHRNELL L O, et al. Effects of locally administered insulin on bone formation in non-diabetic rats [J]. J Biomed Mater Res A, 2013, 101(1): 132-7.
[434] THRAILKILL K, BUNN R C, LUMPKIN C, et al. Loss of insulin receptor in osteoprogenitor cells impairs structural strength of bone [J]. J Diabetes Res, 2014, 2014: 703589.
[435] BARRETT-CONNOR E, KRITZ-SILVERSTEIN D. Does hyperinsulinemia preserve bone? [J]. Diabetes Care, 1996, 19(12): 1388-92.
[436] KNIGHT Z A, SHOKAT K M. Features of selective kinase inhibitors [J]. Chem Biol, 2005, 12(6): 621-37.
[437] KUHAJDA F P, PIZER E S, LI J N, et al. Synthesis and antitumor activity of an inhibitor of fatty acid synthase [J]. Proc Natl Acad Sci U S A, 2000, 97(7): 3450 -4.
[438] WEITZMAN M D, LINDEN R M. Adeno-associated virus biology [J]. AdenoAssociated Virus: Methods and Protocols, 2011: 1-23.
[439] WANG D, TAI P W L, GAO G. Adeno-associated virus vector as a platform for gene therapy delivery [J]. Nat Rev Drug Discov, 2019, 18(5): 358-78.
[440] SAMULSKI R J, MUZYCZKA N. AAV-Mediated Gene Therapy for Research and Therapeutic Purposes [J]. Annu Rev Virol, 2014, 1(1): 427-51.
[441] MINGOZZI F, HIGH K A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy [J]. Blood, 2013, 122(1): 23-36.
[442] DONSANTE A, MILLER D G, LI Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma [J]. Science, 2007, 317(5837): 477.
[443] DEVERMAN B E, PRAVDO P L, SIMPSON B P, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain [J]. Nat Biotechnol, 2016, 34(2): 204-9.
[444] LARGE E E, SILVERIA M A, ZANE G M, et al. Adeno-associated virus (AAV) gene delivery: dissecting molecular interactions upon cell entry [J]. Viruses, 2021, 13(7): 1336.
[445] HUANG W, LIU X, QUEEN N J, et al. Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver [J]. Mol Ther Methods Clin Dev, 2017, 6: 68-78.
[446] KIM Y-C, LEE S E, KIM S K, et al. Toll-like receptor mediated inflammation requires FASN-dependent MYD88 palmitoylation [J]. Nat Chem Biol, 2019, 15(9): 907-16.
[447] BLANQUART C, BARBIER O, FRUCHART J C, et al. Peroxisome proliferatoractivated receptors: regulation of transcriptional activities and roles in inflammation [J]. J Steroid Biochem Mol Biol, 2003, 85(2-5): 267-73.
[448] WAKABAYASHI K-I, OKAMURA M, TSUTSUMI S, et al. The peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha heterodimer targets the histone modification enzyme PR-Set7/Setd8 gene and regulates adipogenesis through a positive feedback loop [J]. Mol Cell Biol, 2009, 29(13): 3544-55.
[449] WEBER D R, HAYNES K, LEONARD M B, et al. Type 1 diabetes is associated with an increased risk of fracture across the life span: a population-based cohort study using The Health Improvement Network (THIN) [J]. Diabetes Care, 2015, 38(10): 1913-20.
[450] FERRON M, WEI J, YOSHIZAWA T, et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism [J]. Cell, 2010, 142(2): 296 -308.
[451] LOOMBA R, MOHSENI R, LUCAS K J, et al. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, PlaceboControlled Phase 2a Trial [J]. Gastroenterology, 2021, 161(5): 1475 -86.
[452] FHU C W, ALI A. Fatty Acid Synthase: An Emerging Target in Cancer [J]. Molecules, 2020, 25(17).
修改评论